XTXiaopeng Tang

Xiaopeng Tang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiaopeng Tang has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Angiotensin II exacerbates intracerebral hemorrhage in mice via heparin-like antithrombin activation and coagulation dysfunction

    by Shaoying Wang, Min Xue, Musan Yan, Chuanfeng Liu, Mengmeng Wang, Yuanjie Yin, Qikai Yin, Shiping Lin, Wenshuo Li, Gan Wang, et al.

  • Inhibiting thromboinflammation via interleukin-4 binding to platelet glycoprotein VI and suppression of thrombosis

    by Shiping Lin, Yuanjie Yin, Shaoying Wang, Chuanfeng Liu, Musan Yan, Xin Jiang, Xin Jin, Qikai Yin, Min Xue, Xiaopeng Tang

    Inflammation and coagulation are intricately linked. Although some studies have documented pro-inflammatory drivers of coagulation, the role of anti-inflammatory cytokines and the underlying mechanisms in the modulation of coagulation, platelet function, and thrombosis remain poorly characterized. In this study, we demonstrated that interleukin-4 (IL-4), an anti-inflammatory cytokine, plays a crucial role in regulating platelet function and thrombus formation. IL-4 inhibited collagen-induced intracellular calcium mobilization, P-selectin expression, ATP release, integrin αIIbβ3 activation, platelet spreading, and platelet aggregation. IL-4 binds to residues 38-46 within GPVI's extracellular collagen-binding domain and suppresses downstream signaling by inhibiting phosphorylation of phospholipase Cγ2 and protein kinase C. A GPVI-derived interfering peptide (RR9) binding to IL-4 disrupted the IL-4-GPVI complex and reversed the inhibitory effects of IL-4 on platelets. In vivo, IL-4 overexpression or intravenous administration inhibited platelet intracellular calcium mobilization, ATP release, and aggregation, prolonged bleeding time, and attenuated both arterial and venous thrombosis. Conversely, IL-4 knockout, anti-IL-4 antibody treatment, or RR9 treatment enhanced platelet reactivity, promoted hemostasis, and aggravated thrombosis. Our findings reveal that IL-4 negatively regulates platelet function through direct interaction with GPVI, thereby facilitating crosstalk among inflammation, hemostasis, and thrombosis. Therefore, modulating IL-4 levels provides a novel strategy for treatment of thrombotic disorders.


  • Open Access

    Inhibiting thromboinflammation with a designed peptide that blocks the IL-1β-FXIa axis uncouples antithrombosis from bleeding risk

    by Yuewei Wang, Qikai Yin, Xin Jiang, Wenshuo Li, Musan Yan, Chuanfeng Liu, Shaoying Wang, Mengmeng Wang, Shiping Lin, Xin Jin, et al.

    The complex interplay between inflammation and coagulation drives thromboinflammatory disorders. While previous studies have shown that interleukin-1β (IL-1β) can induce a hypercoagulable state in response to tissue hypoxia and inflammation, the specific mechanisms of its action on the coagulation cascade remain unclear. Here, we demonstrate that IL-1β directly potentiates key coagulation factors (FXIa, FXa, thrombin, and kallikrein) to accelerate thrombosis. Mechanistically, IL-1β enhances FXIa enzymatic activity through specific binding to its exosite domain. Additionally, we established an IL-1β-FXIa interaction model, based on which the inhibitory peptide QK10 was derived to specifically disrupt their interaction interface and effectively block IL-1β's potentiation of FXIa. Critically, in multiple thrombosis models, QK10 exhibited significant antithrombotic efficacy at doses equal to low molecular weight heparin (LMWH). Notably, bleeding assays revealed a significantly lower bleeding risk with QK10 compared to LMWH. Notably, QK10 also demonstrated promising anti-stroke efficacy in ischemic stroke models. Taken together, these findings establish QK10 as a viable therapeutic candidate that targets the IL-1β-FXIa prothrombotic axis for disruption, features enhanced safety, and offers a new approach to treating thrombo-inflammatory conditions, including ischemic stroke.


  • Estrogen upregulates lactoferrin to induce hypercoagulability for hemostatic protection during pregnancy

    by Ruomei Cheng, Xiaopeng Tang, Xiaoshan Huang, Xudong Dong, Yifan Chen, Jinai Gao, Long Bai, Dawit Adisu Tadese, Quxi Zhao, Meiquan Li, et al.

    Venous thromboembolism (VTE) remains a leading contributor to maternal morbidity and mortality during pregnancy and the immediate postpartum period. Although pregnancy is recognized as a hypercoagulable state, the molecular mechanisms underlying this prothrombotic shift remain incompletely characterized. In this study, lactoferrin was identified as an enhancer of coagulation factor XIa (FXIa) activity. Elevated plasma concentrations of lactoferrin were observed in pregnant women and found to be estrogen dependent, mediated through estrogen response elements (EREs) within the lactoferrin gene promoter. In murine models, pregnancy-induced thrombotic pathology was ameliorated by either genetic knockout of lactoferrin or pharmacological blockade using HS9, a peptide that selectively inhibits lactoferrin-mediated potentiation of FXIa. Notably, HS9 (1 mg/kg) exhibited a substantially reduced hemorrhagic profile compared with low-molecular-weight heparin. These findings identify lactoferrin as a physiological modulator of gestational hypercoagulability and implicate it as a potential therapeutic target for pregnancy-associated VTE, with the capacity to reduce thrombotic risk while preserving hemostatic integrity.


  • Open Access

    Mevalonic acid exerts procoagulant effect by potentiating factor Xa

    by Liyuan Niu, Chuanfeng Liu, Shaoying Wang, Qikai Yin, Shiping Lin, Musan Yan, Wenshuo Li, Yuanjie Yin, Wei Wang, Wenjuan Yu, et al.

    Thrombosis pathogenesis is closely linked to dysregulated lipid metabolism and inflammatory processes. However, the direct regulatory role of mevalonate pathway within the coagulation cascade is still not well understood. This study aimed to elucidate the regulatory effects of mevalonic acid (MVA) on the coagulation system. The effects of MVA on coagulation were measured by recalcification. Enzymatic kinetic analysis and natural substrate hydrolysis assays were performed to identify the coagulation target of MVA. Mice bleeding and thrombosis models were applied to evaluate the effects of MVA administration on hemostasis and thrombosis. Our current study reveals that MVA significantly accelerates plasma coagulation through potentiating the procoagulant activity of FXa, without influencing the platelet aggregation. Studies showed that MVA administration substantially shortened activated partial thromboplastin time, prothrombin time, and reduced bleeding time in both tail bleeding and saphenous vein injury models. Furthermore, using ferric chloride-induced thrombosis, deep vein thrombosis and cerebral infarction models, we observed that MVA markedly potentiated thrombus formation and stroke. Our findings establish for the first time that MVA directly regulates FXa procoagulant activity, while also suggesting potential crosstalk between lipid metabolic pathways and inflammatory signaling in coagulation modulation. These results provide novel mechanistic insights into coagulation abnormalities associated with metabolic disorders such as atherosclerosis and diabetes, highlighting the mevalonate pathway as a potential therapeutic target for thrombotic complications. Graphical Abstract


  • Apolipoprotein A-IV regulates coagulation and ischemic stroke by potentiating activated protein C

    by Musan Yan, Yuewei Wang, Liyuan Niu, Shaoying Wang, Haichu Yu, Qikai Yin, Dachuan Zhang, Yunduo Bai, Yuanjie Yin, Shiping Lin, et al.


  • Open Access

    Deficiency of neutrophil gelatinase-associated lipocalin elicits a hemophilia-like bleeding and clotting disorder in mice

    by Min Xue, Shaoying Wang, Changjiang Li, Yuewei Wang, Ming Liu, Xiaoshan Huang, Gan Wang, Qikai Yin, Dandan Xiao, Shuo Yang, et al.

    Coagulation is related to inflammation, but the key pathway, especially innate immune system and coagulation regulation, is not well understood and need to be further explored. Here, we demonstrated that neutrophil gelatinase-associated lipocalin (NGAL), an innate immune inflammatory mediator, is upregulated in patients with thrombosis. Furthermore, it contributes to the initiation and amplification of coagulation, hemostasis, and thrombosis. This occurs by enhancing tissue factor expression on the cell surface, potentiating various clotting factors such as thrombin, kallikrein, factor XIa (FXIa), and FVIIa, promoting thrombin-induced platelet aggregation, and inhibiting antithrombin. NGAL knockout led to strikingly prolonged clot reaction time and kinetic time in thromboelastography analysis, along with reduced thrombus generation angle and lower thrombus maximum amplitude, which were in line with remarkably prolonged activated partial thromboplastin time and prothrombin time. In several mouse hemostasis and thrombosis models, NGAL overexpression or IV administration promoted coagulation and hemostasis and aggravated thrombosis, whereas NGAL knockout or treatment with anti-NGAL monoclonal antibody significantly prolonged bleeding time and alleviated thrombus formation. Notably, NGAL knockout prolonged mouse tail bleeding time or artery occlusion time to over 40 or 60 minutes, respectively, resembling uncontrollable bleeding and clotting disorder seen in hemophilic mice. Furthermore, anti-NGAL monoclonal antibody treatment markedly reduced the formation of blood clots in inflammation-induced thrombosis models. Collectively, these findings unveil a previously unidentified role of NGAL in the processes of coagulation, hemostasis, and thrombosis, as well as the cross talk between innate immunity, inflammation, and coagulation. Thus, modulating NGAL levels could potentially help balance thrombotic and hemorrhagic risks.


  • Open Access

    NGAL deficiency elicits Hemophilia-like bleeding and clotting disorder

    by Min Xue, Shaoying Wang, Changjiang Li, Yuewei Wang, Ming Liu, Dandan Xiao, Qikai Yin, Liyuan Niu, Chuanbin Shen, Jianxun Wang, et al.

    Coagulation is related to inflammation, but the key pathways, especially innate immunity inflammatory response-coagulation, hemostasis, and thrombosis regulation is poorly understood and need to be further explored. In the current study, we showed that innate immunity inflammatory mediator neutrophil gelatinase-associated apolipoprotein (NGAL) which was upregulated in plasma of deep vein thrombosis patients interacted with and potentiated thrombin, kallikrein, FXIa, and FVIIa and suppressed antithrombin to induce coagulation, hemostasis, and thrombosis. Furthermore, NGAL can augment thrombin-induced platelet aggregation. In multiple mice hemostasis and thrombosis models, NGAL overexpression or intravenous administration promoted coagulation and hemostasis and aggravated thrombus, whereas NGAL knockout or treatment with anti-NGAL monoclonal antibody significantly prolonged bleeding time and alleviated thrombus formation. Notably, NGAL knockout prolonged both mice tail bleeding time and artery occlusion time to over 40 min, resembling uncontrollable bleeding and clotting disorder seen in Hemophilia mice. Furthermore, anti-NGAL monoclonal antibody treatment markedly reduced the formation of blood clots in a mouse-tail thrombosis model induced by carrageenan, which is linked to inflammation. Collectively, these findings suggest NGAL is a crucial coagulation regulator and mediates the crosstalk between innate immunity inflammation and coagulation, hemostasis, and thrombus, and provide new target and strategy for the development of innovative antithrombotic drugs.

  • Open Access

    An inhibitor of leukotriene-A 4 hydrolase from bat salivary glands facilitates virus infection

    by Mingqian Fang, Xiaopeng Tang, Juan Zhang, Zhiyi Liao, Gan Wang, Ruomei Cheng, Zhiye Zhang, Hongwen Zhao, Jing Wang, Zhaoxia Tan, et al.

    Significance: An immunosuppressant protein (MTX), which facilitates virus infection by inhibiting leukotriene A 4 hydrolase (LTA 4 H) to produce the lipid chemoattractant leukotriene B 4 (LTB 4 ), was identified and characterized from the submandibular salivary glands of the bat Myotis pilosus . To the best of our knowledge, this is a report of an endogenous LTA 4 H inhibitor in animals. MTX was highly concentrated in the bat salivary glands, suggesting a mechanism for the generation of immunological privilege and immune tolerance and providing evidence of viral shedding through oral secretions. Moreover, given that the immunosuppressant MTX selectively inhibited the proinflammatory activity of LTA 4 H, without affecting its antiinflammatory activity, MTX might be a potential candidate for the development of antiinflammatory drugs by targeting the LTA 4 -LTA 4 H-LTB 4 inflammatory axis.